Déjà Vu In England: Lilly’s Alzheimer’s Drug Kisunla Gets MHRA Yes, But NICE Says No

Lilly’s Kisunla has hit the same barrier as its competitor, Eisai/Biogen’s Leqembi, in England.

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".